FDA Approves Cabozantinib for Adults and Paediatric Patients 12 Years of Age and Older with pNET and epNET By Ogkologos - April 18, 2025 719 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the CABINET study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR Perguntas frequentes sobre COVID-19 e câncer: respostas para pacientes e sobreviventes June 23, 2020 FDA Authorizes Blood Test for Assessing Risk of Hereditary Cancers November 2, 2023 Effects of Patient Navigation, Lower-Cost Drug Alternatives on the Cost of... September 26, 2022 TAT 2021 Honorary Award: A Recognition in Cancer Drug Development to... February 16, 2021 Load more HOT NEWS Creating a shared vision to detect cancer earlier The Cancer Moonshot: Moving from Planning to Research Cancer Research UK’s charity Christmas cards now available FDA Grants Accelerated Approval to Elranatamab-bcmm for Multiple Myeloma
